Europe’s pharma industry saw a rise of 1.2% in overall deal activity during Q2 2019, when compared to the four-quarter average, according to GlobalData’s deals database.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
A total of 85 deals worth $89.8bn were announced for the region during Q2 2019, against the last four-quarter average of 84 deals.
Of all the deal types, venture financing saw most activity in Q2 2019 with 39, representing a 45.9% share for the region.
In second place was M&A with 36 deals, followed by private equity deals with ten transactions, respectively capturing a 42.4% and 11.8% share of the overall deal activity for the quarter.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIn terms of value of deals, M&A was the leading category in Europe’s pharma industry with $87.84bn, while private equity and venture financing deals totalled $1.56bn and $398.28m, respectively.
Europe pharma industry deals in Q2 2019: Top deals
The top five pharma deals accounted for 98.7% of the overall value during Q2 2019.
The combined value of the top five pharma deals stood at $88.66bn, against the overall value of $89.8bn recorded for the quarter. The top announced pharma deal tracked by GlobalData in Q2 2019 was AbbVie’s $85.74bn acquisition of Allergan.
In second place was the $1.24bn private equity deal with DOC Generici by Intermediate Capital Group and Merieux Equity Partners and in third place was Pfizer’s $810m acquisition of Therachon.
The $519.43m asset transaction with NovImmune by Swedish Orphan Biovitrum and Karo Pharma‘s acquisition of Trimb Healthcare for $360.71m held fourth and fifth positions, respectively.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.
